Other News To Note
Monday, August 15, 2011
Kineta Inc., of Seattle, received a $2.8 million Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease to support work on a new class of antiviral drugs. Kineta's program focuses on agonists of the retinoic acid inducible gene 1 innate immune pathway and is designed to target RNA viruses such as hepatitis C, influenza, West Nile virus, respiratory syncytial virus, Dengue fever and the common cold.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.